With the support by the National Natural Science Foundation of China,the joint research team directed by Prof.Xia NingShao(夏宁邵)at the State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,Xiamen U...With the support by the National Natural Science Foundation of China,the joint research team directed by Prof.Xia NingShao(夏宁邵)at the State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,Xiamen University,and Prof.Li Jun(李君)at the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,Zhejiang University,recently reported the HBV infection-induced liver cirrhosis development in dual-humanised mice with robust differentiation and proliferation of human hepatocytes and multiple immune cells.展开更多
Objective To explore clinical efficacy of Yiguanjian Decoction(YD)combined Adefovir Dipivoxil Tablet(ADT)in treating HBe Ag negative chronic viral hepatitis B(CVHB)active compensated liver cirrhosis(LC)patients.Method...Objective To explore clinical efficacy of Yiguanjian Decoction(YD)combined Adefovir Dipivoxil Tablet(ADT)in treating HBe Ag negative chronic viral hepatitis B(CVHB)active compensated liver cirrhosis(LC)patients.Methods Totally 68 HBe Ag negative CVHB active compensated LC patients initially treated were assigned to the treatment group and the control group展开更多
Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide,with 75% of those affected distributed in the Asia-Pacific region.Approximately one million HBV-infected patients die of liver cirrhosis ...Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide,with 75% of those affected distributed in the Asia-Pacific region.Approximately one million HBV-infected patients die of liver cirrhosis and hepatocellular carcinoma (HCC) each year.If left untreated,6-20% of chronic hepatitis B (CrHB) patients will develop cirrhosis over five years.The cumulative incidence of HBV-related cirrhosis,disease progression,and prognosis are closely associated with serum HBV DNA levels.Antiviral therapy in HBV-related cirrhosis has been documented by several long-term cohort studies to decrease disease progression to hepatic decompensation and HCC.The approval and availability of oral antiviral agents with better safety profiles has greatly improved the prognosis for HBV-related cirrhosis.Here,we discuss the significance of antiviral therapy for HBV-related cirrhosis and the management of HBV-related diseases in the future.展开更多
文摘With the support by the National Natural Science Foundation of China,the joint research team directed by Prof.Xia NingShao(夏宁邵)at the State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics,Xiamen University,and Prof.Li Jun(李君)at the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,Zhejiang University,recently reported the HBV infection-induced liver cirrhosis development in dual-humanised mice with robust differentiation and proliferation of human hepatocytes and multiple immune cells.
文摘Objective To explore clinical efficacy of Yiguanjian Decoction(YD)combined Adefovir Dipivoxil Tablet(ADT)in treating HBe Ag negative chronic viral hepatitis B(CVHB)active compensated liver cirrhosis(LC)patients.Methods Totally 68 HBe Ag negative CVHB active compensated LC patients initially treated were assigned to the treatment group and the control group
基金the National Key Technologies Research and Development Program of China during the 11th/12th Five-year Plan Period (no.2008ZX1002-006,2012ZX10002007-001-040 and 2013ZX10002004-002-003)
文摘Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide,with 75% of those affected distributed in the Asia-Pacific region.Approximately one million HBV-infected patients die of liver cirrhosis and hepatocellular carcinoma (HCC) each year.If left untreated,6-20% of chronic hepatitis B (CrHB) patients will develop cirrhosis over five years.The cumulative incidence of HBV-related cirrhosis,disease progression,and prognosis are closely associated with serum HBV DNA levels.Antiviral therapy in HBV-related cirrhosis has been documented by several long-term cohort studies to decrease disease progression to hepatic decompensation and HCC.The approval and availability of oral antiviral agents with better safety profiles has greatly improved the prognosis for HBV-related cirrhosis.Here,we discuss the significance of antiviral therapy for HBV-related cirrhosis and the management of HBV-related diseases in the future.
